Ginkgo Bioworks Expands Commitment at Marcus Partners Life Science Campus at Parcels O & P in Raymond L. Flynn Marine Park
Seaport Project is Now Fully Leased; Construction Expected to Start in 2022
MARCUS PARTNERS, a real estate investment, management and development firm announced today that GINKGO BIOWORKS (NYSE: DNA), the organism company, will occupy 100% of the firm’s new life science campus at Parcels O and P in the Raymond L. Flynn Marine Park (RLFMP) in the South Boston Waterfront neighborhood. Previously announced as the anchor tenant, Ginkgo Bioworks is now committed to the entire 228,000SF life science campus.
At Parcel O, Marcus Partners is planning a new state-of-the-art 219,000SF life science building. An adaptive reuse of an existing steel manufacturing building at Parcel P will serve as a 9,000SF amenity building for the campus. Construction commencement is expected in early 2022.
“Ginkgo Bioworks is committed to growth, and we are pleased to help create a home for them to continue to expand while remaining grounded in this neighborhood,” said Marcus Partners Principal Patrick Sousa. “The developing South Boston Waterfront cluster is creating an exciting ecosystem of life science innovators, and we are pleased to be a part of the community.”
The new building design is a modern interpretation of the district’s industrial vernacular, aiming to celebrate the RLFMP’s industrial ecosystem while offering a forward-looking expression. The adaptive reuse of the existing steel manufacturing building works to further enhance the industrial character of the neighborhood.
“As Ginkgo Bioworks expands their existing footprint in Raymond L. Flynn Marine Park, the neighborhood takes a step further to solidify its role in the innovation economy,” said Marcus Partners Principal Levi Reilly. “We are committed to supporting the city, state and community stakeholders with their goals for this area and partnering with them ahead.”
“Boston’s Seaport District is an absolutely thriving area for the biotechnology industry. We’re thrilled to be building out more foundries and workspaces in these innovative new facilities right next to the headquarters where we presently run and grow our business,” added Barry Canton, Chief Technology Officer at Ginkgo Bioworks.
Marcus Partners is one of the first development firms to join the City’s Climate Resiliency Infrastructure Fund, and the project is designed to achieve LEED Gold certification by an architectural joint venture between SGA and DREAM Collaborative. Construction will be managed by John Moriarty & Associates in a joint venture with a Minority or Women-Owned Business Enterprise.
John Carroll, Evan Gallagher and Curtis Cole of Colliers International represented Marcus Partners. Anne Columbia and Patrick Downey of Columbia Group Realty Advisors, Inc. represented Ginkgo Bioworks.
About Marcus Partners
Marcus Partners is a vertically integrated real estate firm with a strong history of successful investment, management and development. The firm is based in Boston, with regional offices in Metro New York City and Metro Washington, D.C. The firm focuses on strategic and opportunistic investment strategies across multifamily, industrial, life science and other property types where it can create value and maximize risk-adjusted returns. Its current portfolio includes approximately seven million square feet of commercial real estate along the East Coast. For more information, please visit WWW.MARCUSPARTNERS.COM.
About Ginkgo Bioworks
Ginkgo is building a platform to enable customers to program cells as easily as we can program computers. The company’s platform is enabling biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. Ginkgo has also actively supported a number of COVID-19 response efforts, including K-12 pooled testing, vaccine manufacturing optimization and therapeutics discovery. For more information, visit WWW.GINKGOBIOWORKS.COM.
Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws, including statements regarding the benefits of the lease expansion and Ginkgo’s expectations concerning its growth. These forward-looking statements generally are identified by the words “believe,” “project,” “potential,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this document, including but not limited to: (i) the effect of the business combination with Soaring Eagle Acquisition Corp. (“Soaring Eagle”) on Ginkgo’s business relationships, performance, and business generally, (ii) risks that the business combination disrupts current plans of Ginkgo and potential difficulties in Ginkgo’s employee retention, (iii) the outcome of any legal proceedings that may be instituted against Ginkgo or against Soaring Eagle related to the business combination, (iv) volatility in the price of Ginkgo’s securities now that it is a public company due to a variety of factors, including changes in the competitive and highly regulated industries in which Ginkgo plans to operate, variations in performance across competitors, changes in laws and regulations affecting Ginkgo’s business and changes in the combined capital structure, (v) the ability to implement business plans, forecasts, and other expectations after the completion of the business combination, and identify and realize additional opportunities, and (vi) the risk of downturns in demand for products using synthetic biology. The foregoing list of factors is not exhaustive. You should carefully consider the foregoing factors and the other risks and uncertainties described in the “Risk Factors” section of Soaring Eagle’s registration statement on Form S-4 and other documents filed by Ginkgo Bioworks Holdings, Inc. from time to time with the U.S. Securities and Exchange Commission. These filings identify and address other important risks and uncertainties that could cause actual events and results to differ materially from those contained in the forward-looking statements. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and Ginkgo and Soaring Eagle assume no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Neither Ginkgo nor Soaring Eagle gives any assurance that either Ginkgo or Soaring Eagle will achieve its expectations.
Contact
September 2021